D
Synlett
P. R. Patel et al.
Letter
Br
O
H
O
H+ catalyst
O
(from substrate)
hυ
2
x
N
Br
Br Br
N
O
O
N
H
NH
O
CO2 + HBr
Br Br
Br
N
N
N
N
H
H
Scheme 5 Possible mechanism through a radical pathway
the indazole interacts with NBS, most likely through the
carboxylic acid O–H and the carbonyl groups of NBS.
Acknowledgment
We would like to thank Surila Darbar, David Townrow, and Keith
Holding for their help with LC/MS, NMR, and managing the laborato-
ry, respectively, and Dr. Ryan West for helpful discussions.
1
With the H NMR evidence suggesting that the substrate
is involved in the activation of NBS towards dissociation,
and the use of a radical quencher stopping the reaction,
even in the apparent presence of bromine, we believe it is
highly likely that the reaction proceeds by a radical path-
way. Although not definitive, a possible mechanism is
shown in Scheme 5. The reaction is initiated by protonation
of NBS by the indazolecarboxylic acid, which helps to acti-
vate the N–Br bond towards homolytic cleavage to form
bromine. The bromine then undergoes light-mediated
and/or thermal homolytic cleavage to produce bromine
radicals. A bromine radical abstracts the acidic proton of
the indazolecarboxylic acid, and subsequent decarboxyl-
ation produces an indazole free radical that reacts with an-
other equivalent of bromine to form the brominated product.
Having previously established that azaheteroarene car-
boxylic acids undergo metal- and catalyst-free decarboxyl-
ative halogenation, we sought to investigate the mechanism
by which the reaction occurs. Although we cannot com-
pletely rule out alternative mechanisms, our studies sug-
gest that the reaction proceeds by a radical pathway. The
yield of the reaction is higher when the chemistry is con-
ducted in the presence of light, and the reaction fails to pro-
ceed in the presence of the radical quencher TEMPO. We
believe that the acidic reaction environment influences the
reactivity of NBS, and so catalyses the formation of bromine
that subsequently reacts through a radical pathway to form
the decarboxylative brominated product.
Supporting Information
Supporting information for this article is available online at
https://doi.org/10.1055/s-0040-1707901.
S
u
p
p
orti
n
g Inform ati
o
n
S
u
p
p
orti
n
g Inform ati
o
n
References and Notes
(1) Pozharskii, A. F.; Soldatenkov, A. T.; Katritzky, A. R. Heterocycles
in Life and Society: An Introduction to Heterocyclic Chemistry,
Biochemistry and Applications, 2nd ed; Wiley: Chichester, 2011.
(2) Heterocyclic Chemistry in Drug Discovery; Li, J. J., Ed.; Wiley:
Hoboken, 2013.
(
(
3) Pathak, T. P.; Miller, S. J. J. Am. Chem. Soc. 2012, 134, 6120.
4) Chung, W.-J.; Vanderwal, C. D. Angew. Chem. Int. Ed. 2016, 55,
4396.
(
5) Bacsa, I.; Herman, B. E.; Jójárt, R.; Herman, K. S.; Wölfling, J.;
Schneider, G.; Varga, M.; Tömböly, C.; Rižne, T. L.; Szécsi, M.;
Mernyák, E. J. Enzyme Inhib. Med. Chem. 2018, 33, 1271.
(6) Mallinger, A.; Schiemann, L.; Rink, C.; Sejberg, J.; Honey, M. A.;
Czodrowski, P.; Stubbs, M.; Poeschke, O.; Busch, M.; Schneider,
R.; Schwarz, D.; Musil, D.; Burke, R.; Urbahns, K.; Workman, P.;
Wienke, D.; Clarke, P. A.; Raynaud, F. I.; Eccles, S. A.; Esdar, C.;
Rohdich, F.; Blagg, J. ACS Med. Chem. Lett. 2016, 7, 573.
(7) Li, F.; Hu, Y.; Wang, Y.; Ma, C.; Wang, J. J. Med. Chem. 2017, 60,
1580.
(8) Li J. J.; In Name Reactions; Springer, Berlin, 2009; 298; DOI:
10.1007/978-3-642-01053-8_131
(
9) Fu, Z.; Li, Z.; Song, Y.; Yang, R.; Liu, Y.; Cai, H. J. Org. Chem. 2016,
1, 2794.
(10) Jiang, Q.; Li, H.; Zhang, X.; Xu, B.; Su, W. Org. Lett. 2018, 20,
424.
8
Funding Information
2
Biotechnology
BB/L017105/1).
and
Biological
Sciences
Research
Council
(
B
i
ote
c
h
n
o
l
o
g
y
a
n
d
B
i
o
l
o
g
i
c
a
lS
c
i
e
n
c
es
R
esearc
h
C
o
u
n
c
i
l (BB/L
0
1
7
1
0
5/1)
©
2020. Thieme. All rights reserved. Synlett 2020, 31, A–E